24 Jun 2024 • A study in Scotland found that fenofibrate significantly reduced the progression of diabetic retinopathy in adults with early retinal changes.

• 1151 adults with nonreferable diabetic retinopathy or maculopathy were recruited and followed (median 4 years). They were randomly assigned to receive either fenofibrate tablets 145 mg or a placebo.

• The study found that in the fenofibrate group, there was a lower occurrence (22.7%) of referable diabetic retinopathy or maculopathy compared to the placebo group (29.2%). The fenofibrate group also had lower frequencies (32.1%) of retinopathy or maculopathy progression and macular edema development compared to the placebo group (40.2%).

• However, there was no impact on visual function, quality of life, or visual acuity. Serious adverse events occurred in both groups at similar rates.

Source:NEJM| Read full story